NCT01845740View on ClinicalTrials.gov

Phase Ib Study of SC Milatuzumab in SLE

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Lupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, SystemicLupus Vasculitis, Central Nervous SystemLupus Nephritis
Interventions
DRUG

milatuzumab

Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.

DRUG

Placebo

Placebo will be administered subcutaneously once weekly for 4 weeks.

Trial Locations (1)

90048

Cedars Sinai Medical Center-Wallace Rheumatic Study Center, West Hollywood

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Gilead Sciences

INDUSTRY

NCT01845740 - Phase Ib Study of SC Milatuzumab in SLE | Biotech Hunter | Biotech Hunter